Key facts
- Panome Bio’s last known valuation is $15.8M.
- It has raised $12.0M across 2 recorded rounds; the latest was Early Stage VC ($6.0M) in Nov 2024.
- Notable investors include BioGenerator Ventures, Telegraph Hill Partners.
- Panome Bio has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($6.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Panome Bio
Funding rounds
2 roundsAbout Panome Bio
Developer of metabolomics technologies designed to facilitate biomarker discovery and metabolite profiling. The company specializes in metabolomics capabilities, comprehensive workflows, and personalized data analysis reports and offers services like global profiling, data analysis reports, and biomarker discovery, providing clients with a global and unbiased view of the metabolome that captures the breadth of diverse metabolites in biological systems.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2022
- Employees
- 25
- Website
- panomebio.com/
- Ownership
- Privately Held (backing)
Panome Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Panome Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Panome Bio in its N-PORT filings yet. We sweep new filings monthly.